Jazz to Buy Actio Biosciences for $820M Upfront, Adding Rare Epilepsy Drug

Jazz Pharmaceuticals (Nasdaq: JAZZ) announced Monday it will acquire privately held Actio Biosciences for $820 million upfront, with up to $500 million in additional milestone payments, adding a clinical-stage precision therapy for a rare genetic epilepsy that has no FDA-approved treatments.

The deal hands Jazz ABS-1230, a first-in-class small molecule KCNT1 ion channel inhibitor. KCNT1+ epilepsy is a devastating developmental and epileptic encephalopathy affecting roughly 2,500 patients in the U.S. Most patients experience dozens to hundreds of seizures daily and are resistant to existing antiseizure medications. About 80% of cases begin in infancy; many children never achieve basic developmental milestones and some do not survive to adulthood.

ABS-1230 has already shown meaningful seizure reductions in an early clinical proof-of-concept trial in children. The ongoing Phase 1b/2a KYRON trial is designed to serve as the registrational study. The drug carries FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations and has been accepted into the FDA’s Rare Disease Evidence Principles program, which aims to speed development of ultra-rare disease therapies.

Jazz has built one of the industry’s strongest rare epilepsy franchises around Epidiolex, its blockbuster cannabidiol oral solution approved in Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. ABS-1230 extends that franchise into a genetically defined patient population with no existing therapeutic options.

“If we close the proposed transaction, we’d combine the emerging clinical profile of ABS-1230 with Jazz’s proven development engine and established commercial infrastructure in rare epilepsies,” said Jazz CEO Renee Gala.

As part of the transaction, Actio will spin out a new privately held company retaining its TRPV4 inhibitor ABS-0871 for Charcot-Marie-Tooth type 2C and other early-stage programs. Jazz will hold a minority stake in the new entity.

The boards of both companies have unanimously approved the deal, which is expected to close by the fourth quarter of 2026. Jazz will fund the acquisition through cash on hand and existing financing facilities.

Jazz shares closed Friday at $256.56. The stock is roughly flat year-to-date.

What to watch: The KYRON registrational trial’s progress will determine whether ABS-1230 can reach an NDA submission. With no approved therapies for KCNT1+ epilepsy, the first company to market could claim the entire addressable population.